Are you on the hunt for big returns to supercharge your portfolio? If you are, then it could pay to listen to what analysts are saying about the ASX 200 stocks listed below. Here's why analysts are feeling bullish about these stocks and are tipping them to rise strongly from current levels: ( ) Bell Potter thinks that Neuren Pharmaceuticals could be a great option for growth investors. It is a company that is developing new drug therapies to treat multiple serious neurological disorders that emerge in early childhood and have no or limited approved treatment options.
Bell Potter is feeling bullish due to the ASX 200 growth stock's product pipeline. It notes that the NNZ-2591 product candidate in particular has the potential to be a big revenue generator. It is being trialled in children with Angelman syndrome.
It explains: Neuren Pharmaceuticals is a biotech company that is well-funded via its first asset, DAYBUE, which is an FDA approved trofinetide for the treatment of Rett syndrome. NEU's value is from its second asset, NNZ-2591, which is under development for rare diseases. NNZ-2591, if successful, could lead to a significant increase in revenue and earnings when brought to market.
NEU looks attractive on a risk/adjusted basis after the recent sell-off. Bell Potter has a buy rating and $25.00 price target on its shares.
Based on its current share price of $12.27, this implies potential upside of 103% for investors. ( ) Another ASX 200 growth stock that could be destined t.
